Literature DB >> 18598763

Poloxamer 407 as a solubilising agent for tolfenamic acid and as a base for a gel formulation.

S Cafaggi1, E Russo, G Caviglioli, B Parodi, R Stefani, G Sillo, R Leardi, G Bignardi.   

Abstract

A solubility phase study was carried out to investigate the ability of Poloxamer 407 (P407) to solubilise tolfenamic acid. P407 considerably enhanced the solubility of this anti-inflammatory agent, by increasing its concentration in aqueous solution at least 2000-fold (up to C=4mM), when present at 12% (w/w) at 25 degrees C. The solubilisation process was spontaneous and exothermic, as indicated by thermodynamic parameters. A mixture experimental design was used to investigate the physical and release properties of P407-based gel formulations. The experimental design allowed verifying that drug release, occurring through a Fickian diffusion mechanism, was independent of the bulk viscosity of the system. The sustained release of tolfenamic acid towards the receptor phase constituted by isopropyl myristate was accompanied, in its early stage, by the concomitant release of ethanol and tetrahydrofurfuryl alcohol (THFA) used as cosolvents to obtain a drug loading of 0.6% (w/w). The poloxamer micellar phase was directly involved in the late stage of drug release, thus indicating that a strong interaction occurred in the gel between the poloxamer and tolfenamic acid. Results point out the possibility of both the systemic and topical administration of tolfenamic acid by means of aqueous solutions or gels containing P407 at an adequate concentration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18598763     DOI: 10.1016/j.ejps.2008.05.010

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  8 in total

1.  Studies on tolfenamic acid-chitosan intermolecular interactions: effect of pH, polymer concentration and molecular weight.

Authors:  Sofia Ahmed; Muhammad Ali Sheraz; Ihtesham Ur Rehman
Journal:  AAPS PharmSciTech       Date:  2013-04-27       Impact factor: 3.246

2.  An In Vitro Evaluation of the Antimicrobial Activity of Probiotics Against Endodontic Pathogens.

Authors:  Garapati Venkata Charan Teja; Mahali Raghu Nandana Raju; Uppu Lavanya Neelima Reddy; Uppalapati V V Satyanarayana; Devatha Praneeth; Kumpatla Maheswari
Journal:  Cureus       Date:  2022-06-30

3.  Development of intramammary delivery systems containing lasalocid for the treatment of bovine mastitis: impact of solubility improvement on safety, efficacy, and milk distribution in dairy cattle.

Authors:  Wen Wang; Yunmei Song; Kiro Petrovski; Patricia Eats; Darren J Trott; Hui San Wong; Stephen W Page; Jeanette Perry; Sanjay Garg
Journal:  Drug Des Devel Ther       Date:  2015-01-22       Impact factor: 4.162

4.  Thermogelling properties of purified poloxamer 407.

Authors:  Amir Fakhari; Marta Corcoran; Alexander Schwarz
Journal:  Heliyon       Date:  2017-08-30

5.  Amino-functionalized poloxamer 407 with both mucoadhesive and thermosensitive properties: preparation, characterization and application in a vaginal drug delivery system.

Authors:  Liqian Ci; Zhigang Huang; Yu Liu; Zhepeng Liu; Gang Wei; Weiyue Lu
Journal:  Acta Pharm Sin B       Date:  2017-05-03       Impact factor: 11.413

6.  Efficacy of instillation of MB49 cells and thermoreversible polymeric gel in urothelial bladder carcinoma immunization.

Authors:  Jhonne Pedro Pedott Santana; Priscyla Daniely Marcato; Tais Nader Chrysostomo Massaro; Naiane Lima Godoy; Fernanda de Freitas Anibal; Ricardo Carneiro Borra
Journal:  Lab Anim Res       Date:  2022-05-05

Review 7.  Poloxamer Hydrogels for Biomedical Applications.

Authors:  Eleonora Russo; Carla Villa
Journal:  Pharmaceutics       Date:  2019-12-10       Impact factor: 6.321

8.  In Situ Gelling Systems Using Pluronic F127 Enhance Corneal Permeability of Indomethacin Nanocrystals.

Authors:  Noriaki Nagai; Takumi Isaka; Saori Deguchi; Misa Minami; Mizuki Yamaguchi; Hiroko Otake; Norio Okamoto; Yosuke Nakazawa
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.